Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
NLS Pharmaceutics AG NLSP
$1.15
-$0.07 (-5.74%)
На 18:04, 12 мая 2023
+421.74%
Потенциал через год
Ключевые показатели
-
Marketcap
44589750.00000000
-
week52high
1.88
-
week52low
0.33
-
Revenue
0
-
P/E TTM
-1
-
Beta
-0.81133400
-
EPS
-1.17000000
-
Last Dividend
0.00000000
-
Next Earnings Date
23 мар 2023 г. в 04:00
Описание компании
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Brookline Capital | Buy | 12 мар 2021 г. | |
| Maxim Group | Buy | 03 мар 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
Accesswire
12 янв 2023 г. в 08:30
Management to Discuss Pipeline Goals and Development Strategies across four Preclinical and 2 Clinical Programs across Multiple Central Nervous System (CNS) Disorders NLS to Webcast its R&D Day Event Tuesday, January 31 at 10:00am EST ZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced plans to showcase its global strategic R&D progress and platform, as well as its product candidate and pipeline goals for 2023, with a focus on rare and complex CNS disorders with unmet medical needs.
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
Accesswire
11 янв 2023 г. в 08:30
ZURICH, SWITZERLAND / ACCESSWIRE / January 11, 2023 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, is pleased to announce its participation in the following upcoming conferences: 2023 BIO CEO & Investor Conference Alex Zwyer, NLS' Chief Executive Officer, will present a company update at the 2023 BIO CEO & Investor Conference on March 12-14, 2023, and will be available for one-on-one meetings with conference attendees.
3 Penny Stocks To Watch If You're Playing The “Stock Market Game”
PennyStocks
01 ноя 2022 г. в 13:15
Hot Penny Stocks To Watch Right Now. The post 3 Penny Stocks To Watch If You're Playing The “Stock Market Game” appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
4 Hot Penny Stocks To Watch This Week
PennyStocks
22 авг 2022 г. в 15:31
Penny stocks to add to your watch list this week. The post 4 Hot Penny Stocks To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
What Know About Buying Penny Stocks on July 22nd
PennyStocks
22 июл 2022 г. в 07:00
Here's what you need to know about buying penny stocks on July 22nd The post What Know About Buying Penny Stocks on July 22nd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.